Hydrocodone Pill Identifier: Mallinckrodt M367 vs. Watson 853 Yellow Oblong Tablets and Fentanyl Counterfeit Detection
Hydrocodone Pill Identifier: Mallinckrodt M367 vs. Watson 853 Yellow Oblong Tablets and Fentanyl Counterfeit Detection
A forensic pharmaceutical guide to identifying authentic M367 white and Watson 853 yellow hydrocodone/APAP 10/325mg tablets while detecting deadly street counterfeits.
CLINICAL TABLET IDENTIFIER
EXECUTIVE CLINICAL SUMMARY
Visual verification of hydrocodone/acetaminophen 10/325mg oral tablets is an essential clinical barrier against lethal medication errors and counterfeit poisoning. As the most widely prescribed Schedule II opioid in American medicine, generic 10/325mg tablets—most notably Mallinckrodt’s white capsule-shaped “M367” tablet and Watson’s iconic yellow oblong “WATSON 853” tablet—are aggressively replicated by illicit drug cartels using hydraulic pill presses laced with deadly synthetic fentanyl. Genuine FDA-approved tablets are manufactured with exact physical dimensions, specific color formulations, precise debossings, and uniform bisect score lines.
01. Comprehensive tablet identification monograph: Major manufacturers
The visual identification table below outlines forensic specifications for genuine FDA-approved generic hydrocodone/APAP 10/325mg oral tablets.
| MANUFACTURER | STRENGTH (OPIOID / APAP) | COLOR / SHAPE | OBVERSE (FRONT) | REVERSE (BACK) | NDC NUMBER |
|---|---|---|---|---|---|
| Mallinckrodt Pharmaceuticals | 10mg / 325mg | White / Capsule-Shaped | M367 | Deep Bisect Score Line | 0406-0367 |
| Watson (Actavis / Teva) | 10mg / 325mg | Yellow / Oblong Oval | WATSON | 853 / Scored | 0591-0853 |
| Qualitest (Par / Vintage) | 10mg / 325mg | White / Oval | V | 36 01 / Scored | 0603-3888 |
| Lupin Pharmaceuticals | 10mg / 325mg | White / Capsule-Shaped | L403 | Deep Bisect Score Line | 68180-0403 |
| Aurobindo Pharma | 10mg / 325mg | White / Capsule-Shaped | U03 | Bisect Score Line | 65862-0708 |
| Tris Pharma | 10mg / 325mg | White / Capsule-Shaped | T 259 | Bisect Score Line | 24979-0259 |
02. Forensic specifications: Authentic Mallinckrodt M367 white tablets
Authentic Mallinckrodt M367 tablets possess distinct physical characteristics:
- Color & Geometry: Crisp, brilliant white, capsule-shaped oral tablet measuring approximately 15.0 mm in length and 7.0 mm in width.
- Debossing Precision: The obverse features an arched letter “M” above the numbers “367”. The numbers are engraved with vertical sidewalls and uniform depth.
- Score Line: The reverse contains a functional bisect score line cleanly bisecting the tablet to permit splitting into two equal 5/162.5mg halves.
- Surface Finish: Smooth, hard enamel finish with zero chalky residue when handled with dry fingers.
03. Forensic specifications: Authentic Watson 853 yellow oblong tablets
The Watson 853 formulation (now produced under the Teva/Actavis generic umbrella) is widely recognized by patients for its light yellow coloration:
- Color & Geometry: Pale yellow, oblong elliptical tablet with smooth beveled edges.
- Debossing Details: The front face is debossed with “WATSON” along the upper horizontal plane. The reverse face features “853” with a horizontal score line separating the numerals.
- Dye Uniformity: The yellow dye (D&C Yellow No. 10) is blended evenly throughout the core matrix, showing zero color mottling, speckling, or surface spotting.
04. The illicit fentanyl counterfeit crisis: Fake M367 and Watson 853 pills
The DEA’s National Forensic Laboratory reports that hydrocodone 10/325mg represents one of the most frequently counterfeited prescription medications in North America. Criminal organizations press lethal quantities of illicit fentanyl (often 2mg to 5mg—enough to kill two to three adult men) into counterfeit M367 and Watson 853 dies. Critical visual red flags of fake street pills include:
- Soft, Crumbly Texture: Counterfeit pills crumble easily or leave thick white/yellow chalk powder in baggies or on skin.
- Uneven Coloring: Dark yellow specks, blotchy discoloration, or faded imprints.
- Misaligned Numbers: Faint, crooked, or shallow “M367” or “853” numbers where the dies were poorly machined.
- Thickness Variations: Noticeable differences in tablet height when stacking pills from the same batch.
05. Pharmacy verification and safe storage safeguards
Authentic hydrocodone tablets are dispensed exclusively through state-licensed retail or digital pharmacies in child-resistant amber plastic vials labeled with the dispensing pharmacy’s NPI number, state license, and exact NDC code. To prevent diversion, accidental pediatric ingestion, and domestic theft, keep medication locked in a steel lockbox at controlled room temperature (68°F to 77°F).
06. Detailed Receptor Neurobiology, CYP2D6 Hydromorphone Bioactivation & APAP Synergy
At the molecular and clinical level, Hydrocodone / APAP combines two distinct, synergistic analgesic compounds designed to attack nociceptive signaling through dual central and peripheral mechanisms:
1. Hydrocodone Component: Hydrocodone is a semi-synthetic phenanthrene opioid agonist that binds selectively to the μ-opioid receptor (MOR) on primary afferent neurons in the dorsal horn substantia gelatinosa and brainstem periaqueductal gray (PAG). Receptor coupling to inhibitory Gi/o proteins inhibits adenylyl cyclase, closes N-type voltage-gated calcium channels, and stimulates inward-rectifying potassium channels. This hyperpolarizes neuronal membranes, dramatically inhibiting presynaptic release of substance P, glutamate, and neurokinins.
Furthermore, hydrocodone undergoes critical hepatic O-demethylation catalyzed by cytochrome P450 2D6 (CYP2D6) into hydromorphone. Hydromorphone exhibits a 6- to 10-fold higher binding affinity for μ-opioid receptors than parent hydrocodone, contributing significantly to clinical analgesia. Patients who are CYP2D6 poor metabolizers experience diminished pain relief, whereas ultra-rapid metabolizers risk exaggerated sedation and respiratory depression.
2. Acetaminophen (APAP) Component: Acetaminophen produces analgesia primarily through central inhibition of cyclooxygenase (COX-1, COX-2, and putative central COX-3/peroxidase variants) and modulation of endogenous cannabinoid and descending serotonergic inhibitory pathways. Unlike NSAIDs, APAP lacks peripheral anti-inflammatory effects and does not cause gastric ulceration or platelet inhibition.
| PHARMACOLOGICAL AGENT | PRIMARY MOLECULAR TARGET | HEPATIC METABOLIC ENZYME | CLINICAL ANALGESIC ROLE | CRITICAL CLINICAL HAZARD |
|---|---|---|---|---|
| Hydrocodone | μ-Opioid Receptor (MOR) Agonism | CYP2D6 (to Hydromorphone) & CYP3A4 (to Norhydrocodone) | Blocks ascending nociceptive pain signaling in spinal cord | Respiratory depression, physical dependence, constipation |
| Acetaminophen (APAP) | Central COX / Peroxidase Site Inhibition | Glucuronidation (55%), Sulfation (30%), CYP2E1 (to NAPQI) | Synergistic pain threshold elevation; opioid-sparing effect | Hepatotoxicity / Centrilobular necrosis at >4,000mg/day |
| Hydromorphone (Metabolite) | High-Affinity μ-Opioid Agonist (Ki ~0.37 nM) | Phase II Glucuronidation via UGT2B7 | Potent amplification of central analgesic efficacy | Toxicity in CYP2D6 ultra-rapid metabolizers |
| NAPQI (Reactive Metabolite) | Hepatocyte macromolecules | Detoxified by intracellular glutathione (GSH) | None (Toxic intermediate) | Glutathione depletion leads to irreversible liver failure |
The combination of hydrocodone with acetaminophen creates potent therapeutic synergy, enabling lower doses of the opioid component while maximizing relief for moderate to severe acute musculoskeletal and post-surgical pain.
07. Hepatic Clearance, Renal Impairment & Beers Criteria Safety
Pharmacokinetic clearance of Hydrocodone / APAP involves dual metabolic pathways for both hydrocodone and acetaminophen, requiring strict clinician oversight across specific organ impairment subgroups:
| PATIENT POPULATION | PHARMACOKINETIC KINETICS | DOSING MODIFICATION DIRECTIVE | CRITICAL CLINICAL MANDATE |
|---|---|---|---|
| Hepatic Impairment (Mild-Moderate) | Impaired APAP glucuronidation and reduced hydrocodone clearance | Cap APAP ≤2,000mg / 24 hours; extend dosing intervals to Q8H-Q12H | Monitor transaminases; avoid in acute hepatitis or liver decompensation |
| Severe Hepatic Cirrhosis (Child-Pugh C) | Glutathione depletion; severe hydrocodone metabolic shunting | CONTRAINDICATED: Extreme hepatotoxicity & encephalopathy risk | NAPQI accumulation precipitates fatal hepatic centrilobular necrosis |
| CYP2D6 Poor Metabolizers (~7% Caucasians) | Minimal conversion of hydrocodone to active hydromorphone | Evaluate alternative analgesics; do not dangerously escalate dose | Escalating doses causes toxic hydrocodone/APAP buildup without pain relief |
| CYP2D6 Ultra-Rapid Metabolizers | Rapid, massive bioactivation into hydromorphone | Initiate at 50% standard starting dose; monitor breathing | High risk of sudden, life-threatening respiratory depression |
| Renal Impairment (CrCl < 30 mL/min) | Prolonged hydrocodone elimination half-life; APAP metabolite retention | Increase dosing intervals to every 8 to 12 hours | Monitor for severe cognitive blunting and respiratory depression |
| Geriatric Patients (≥ 65 Years) | Decreased hepatic mass, diminished renal clearance, CNS sensitivity | Start at lowest manufactured dose (e.g. 5/325mg); Beers Criteria oversight | Proactive bowel management mandatory to prevent severe fecal impaction |
Absolute Daily Acetaminophen (APAP) Ceiling: Under FDA regulations, the total cumulative daily dose of acetaminophen from all sources combined (including OTC cough/cold elixirs, sinus remedies, and headache pills) must never exceed 4,000mg per 24 hours. For chronic or elderly patients, clinicians recommend a safer conservative threshold of 3,000mg daily (or ≤2,000mg in chronic alcohol consumers) to protect hepatic glutathione reserves.
08. Comprehensive Patient Clinical Safety & Dispensing Checklist
Before initiating therapy or taking each scheduled dose of Hydrocodone / APAP, patients, caregivers, and clinical teams must review this standardized clinical verification checklist to prevent life-threatening adverse drug events and fatal toxicities:
PATIENT PRE-ADMINISTRATION SAFETY CRITERIA
- Total Acetaminophen (APAP) Audit: Verify that the patient is not taking ANY other products containing acetaminophen (e.g., Tylenol, DayQuil, NyQuil, Excedrin, Percocet). Total APAP from all sources must never exceed 4,000mg/day (clinically target ≤3,000mg/day).
- Absolute Alcohol Prohibition: Strict zero-tolerance for alcohol. Ethanol massively accelerates liver glutathione depletion (triggering acute liver failure from APAP) while paralyzing brainstem respiratory drive alongside hydrocodone.
- Concurrent Benzodiazepine & Sedative Screen: Check for co-prescribed anti-anxiety drugs (alprazolam, diazepam, lorazepam) or sleep aids. The FDA Boxed Warning strictly advises against co-prescribing without active emergency naloxone on site.
- Emergency Naloxone (Narcan) Access: Ensure household members or caregivers know the location of emergency naloxone nasal spray and how to administer it in case of accidental overdose or respiratory collapse.
- Proactive Bowel Regimen Initiation: Opioids inevitably cause opioid-induced constipation (OIC) by paralyzing gastrointestinal motility. Daily fluid intake, dietary fiber, and scheduled osmotic or stimulant laxatives (senna, PEG 3350) should begin with the very first dose.
- Locked Storage & Disposal Safeguards: Store securely in a locked lockbox out of sight and reach of children, visitors, and pets. Accidental single-tablet ingestion of 10mg hydrocodone can cause fatal respiratory arrest in a toddler.
09. Verified Pharmaceutical Formulations & Prescribing Profiles
Hydro Watson (Hydrocodone / APAP 10/325mg)
Watson 853 yellow oblong oral tablets indicated for moderate to severe acute musculoskeletal pain.
Hydro M367 (Hydrocodone / APAP 10/325mg)
Mallinckrodt M367 white capsule-shaped tablets engineered for consistent dual-action analgesia.
10. Frequently Asked Questions
What pill is white and has M367 stamped on it?
A white capsule-shaped pill stamped with “M367” on one side and a score line on the other is generic Hydrocodone Bitartrate and Acetaminophen 10/325mg manufactured by Mallinckrodt Pharmaceuticals.
What is the yellow oval pill with Watson 853 on it?
A yellow oblong pill debossed with “WATSON” on one side and “853” on the other is generic Hydrocodone Bitartrate and Acetaminophen 10/325mg manufactured by Watson (Actavis/Teva).
Are yellow Watson 853 pills stronger than white M367 pills?
No. Both pills contain the exact same active ingredients: 10mg of hydrocodone and 325mg of acetaminophen. The only difference is the color dye and the manufacturer.
How can you tell if an M367 pill is fake or contains fentanyl?
Counterfeit pills often have blurry or shallow lettering, crumble easily into powder, have inconsistent thickness, or have uneven color speckles. Never take any prescription opioid obtained outside a licensed pharmacy.
11. Clinical References & Regulatory Sources
- FDA CDER. Pillbox Database: Tablet Imprint and Visual Identification for Hydrocodone and Acetaminophen. Source Database.
- United States Drug Enforcement Administration (DEA). One Pill Can Kill: Counterfeit Prescription Drugs Alert. Source Database.
- United States Pharmacopeia (USP). Dissolution, Friability, and Weight Uniformity Standards for Hydrocodone Tablets. Source Database.
Consult a Clinical Pharmacy Specialist
Have questions regarding Hydrocodone / APAP dosing intervals, CYP enzyme interactions, or physician-guided discontinuation protocols? Connect with our licensed clinical pharmacy team for patient safety guidance.
Related Patient Services & Verified Care
Every prescription order is verified by a licensed pharmacist in strict adherence to FDA BeSafeRx protocols.